Condition
Metastatic Non-Small-Cell Lung Cancer
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 3 (1)
Trial Status
Recruiting1
Unknown1
Terminated1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07185997Phase 3Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT03436056Phase 1TerminatedPrimary
PembRolIzuMab and Stereotactic Body Radiotherapy In Metastatic Non-small-cell lunG Cancer Patients
NCT01717105UnknownPrimary
Observational Study to Characterize the Incidence of EGFR Mutation Positive and Advanced NSCLC Patients
Showing all 3 trials